1. Scrip
  3. >>Cardiovascular

Bristol-Myers Squibb Makes First Investment In European VC Fund

 
• By Sukaina Virji

Bristol-Myers Squibb, like Pfizer and GlaxoSmithKline before it, has entered a strategic collaboration with LSP (Life Sciences Partners), a specialist European healthcare investment firm. "This is the first time BMS is partnering with a European healthcare fund and LSP was chosen after a very rigorous selection process," the VC firm told Scrip.

Bristol-Myers Squibb, like Pfizer and GlaxoSmithKline before it, has entered a strategic collaboration with LSP (Life Sciences Partners), a specialist European healthcare investment firm. "This is the first time BMS is partnering with a European healthcare fund and LSP was chosen after a very rigorous selection process," the VC firm told Scrip.

LSP, which has raised more than €1bn since its inception 25 years ago, has provided start-up and growth capital to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.